A unique four-hub protein cluster associates to glioblastoma progression

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Simeone, Pasquale ^a   Trerotola, Marco ^a   Urbanella, Andrea ^a   Lattanzio, Rossano ^a   Ciavardelli, Domenico ^a,b   Di Giuseppe, Fabrizio ^a,c   Eleuterio, Enrica ^a,c   Sulpizio, Marilisa ^a,c   Eusebi, Vincenzo ^d   Pession, Annalisa ^e   Piantelli, Mauro ^a   Alberti, Saverio ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b KORE UNIVERSITY OF ENNA   (Italy)

^c Stem TeCh Group   (Italy)

^d FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^e BELLARIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; HUNTINGTIN; MYC PROTEIN; PROTEIN 14 3 3; PROTEIN 14 3 3 ZETA; PROTEIN P53; UNCLASSIFIED DRUG; PROTEOME; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER GRADING; CHILD; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; GENE CLUSTER; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PARTIAL LEAST SQUARES REGRESSION; PATHOGENESIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRESCHOOL CHILD; PRINCIPAL COMPONENT ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; SCHOOL CHILD; SIGNAL TRANSDUCTION; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING; YOUNG ADULT; BRAIN; BRAIN TUMOR; CLUSTER ANALYSIS; GLIOMA; METABOLISM; MULTIVARIATE ANALYSIS; PATHOLOGY; PROCEDURES; PROTEIN PROTEIN INTERACTION;

BIOMARKERS, TUMOR; BRAIN; BRAIN NEOPLASMS; CLUSTER ANALYSIS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; MULTIVARIATE ANALYSIS; PROTEIN INTERACTION MAPS; PROTEOME; PROTEOMICS; SIGNAL TRANSDUCTION;

EID: 84904693932     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103030     Document Type: Article

References (87)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30.
2. Louis D, Ohgaki H, Wiestler O, Cavenee W (2007) World Health Organization Classification of Tumours of the Central Nervous System. Lyon: IARC Press.
3. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109. (Pubitemid 47103521)
4. De Vita VT, Lawrence TS, Rosenberg SA (2008) De Vita, Hellman & Rosenberg's Cancer: Principles & Practice of Oncology, 8th Edition; De Vita VT, Hellman S, Rosenberg SA, editors. Philadelphia: Lippincott Williams & Wilkins.
5. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, et al. (2002) The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61: 215-225; discussion 226-219.
6. Aldape K, Simmons ML, Davis RL, Miike R, Wiencke J, et al. (2000) Discrepancies in diagnoses of neuroepithelial neoplasms: the San Francisco Bay Area Adult Glioma Study. Cancer 88: 2342-2349. (Pubitemid 30247135)
7. Radner H, Blumcke I, Reifenberger G, Wiestler OD (2002) [The new WHO classification of tumors of the nervous system 2000. Pathology and genetics]. Pathologe 23: 260-283.
8. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, et al. (2004) Genetic pathways to glioblastoma: a population-based study. Cancer Res 64: 6892-6899. (Pubitemid 39330996)
9. Rasheed BK, Wiltshire RN, Bigner SH, Bigner DD (1999) Molecular pathogenesis of malignant gliomas. CurrOpinOncol 11: 162-167. (Pubitemid 29229607)
10. Rich JN, Bigner DD (2004) Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov 3: 430-446. (Pubitemid 38618125)
11. Yang L, Luquette LJ, Gehlenborg N, Xi R, Haseley PS, et al. (2013) Diverse mechanisms of somatic structural variations in human cancer genomes. Cell 153: 919-929.
12. Frattini V, Trifonov V, Chan JM, Castano A, Lia M, et al. (2013) The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet.
13. Chen J, McKay RM, Parada LF (2012) Malignant glioma: lessons from genomics, mouse models, and stem cells. Cell 149: 36-47.
14. Bleeker FE, Molenaar RJ, Leenstra S (2012) Recent advances in the molecular understanding of glioblastoma. J Neurooncol 108: 11-27.
15. Chumbalkar V, Sawaya R, Bogler O (2008) Proteomics: the new frontier also for brain tumor research. Curr Probl Cancer 32: 143-154. (Pubitemid 351697558)
16. Hanash SM, Bobek MP, Rickman DS, Williams T, Rouillard JM, et al. (2002) Integrating cancer genomics and proteomics in the post-genome era. Proteomics 2: 69-75. (Pubitemid 34273100)
17. Odreman F, Vindigni M, Gonzales ML, Niccolini B, Candiano G, et al. (2005) Proteomic studies on low- and high-grade human brain astrocytomas. J Proteome Res 4: 698-708. (Pubitemid 40863258)
18. Okamoto H, Li J, Glasker S, Vortmeyer AO, Jaffe H, et al. (2007) Proteomic Comparison of Oligodendrogliomas with and without 1pLOH. Cancer Biol Ther 6: 391-396. (Pubitemid 47328307)
19. Niclou SP, Fack F, Rajcevic U (2010) Glioma proteomics: status and perspectives. J Proteomics 73: 1823-1838.
20. Gimenez M, Souza VC, Izumi C, Barbieri MR, Chammas R, et al. (2010) Proteomic analysis of low- to high-grade astrocytomas reveals an alteration of the expression level of raf kinase inhibitor protein and nucleophosmin. Proteomics 10: 2812-2821.
21. Marucci G, Morandi L, Magrini E, Farnedi A, Franceschi E, et al. (2008) Gene expression profiling in glioblastoma and immunohistochemical evaluation of IGFBP-2 and CDC20. Virchows Arch 453: 599-609.
22. Bjellqvist B, Pasquali C, Ravier F, Sanchez JC, Hochstrasser D (1993) A nonlinear wide-range immobilized pH gradient for two-dimensional electrophoresis and its definition in a relevant pH scale. Electrophoresis 14: 1357-1365. (Pubitemid 24042920)
23. Hochstrasser D, Harrington M, Hochstrasser A, Miller M, Merril C (1988) Methods for increasing the resolution of two-dimensional protein electrophoresis. Anal Biochem 173: 424-435.
24. McLeod J, Curtis N, Lewis HD, Good MA, Fagan MJ, et al. (2009) Gamma-secretase-dependent cleavage of amyloid precursor protein regulates osteoblast behavior. FASEB J 23: 2942-2955.
25. Xia J, Psychogios N, Young N, Wishart DS (2009) MetaboAnalyst: a web server for metabolomic data analysis and interpretation. Nucleic Acids Res 37: W652-660.
26. Xia J, Wishart DS (2011) Web-based inference of biological patterns, functions and pathways from metabolomic data using MetaboAnalyst. Nat Protoc 6: 743-760.
27. Xia J, Mandal R, Sinelnikov IV, Broadhurst D, Wishart DS (2012) MetaboAnalyst 2.0-a comprehensive server for metabolomic data analysis. Nucleic Acids Res.
28. Eriksson L, Antti H, Gottfries J, Holmes E, Johansson E, et al. (2004) Using chemometrics for navigating in the large data sets of genomics, proteomics, and metabonomics (gpm). Anal Bioanal Chem 380: 419-429.
29. Arndt D, Xia J, Liu Y, Zhou Y, Guo AC, et al. (2012) METAGENassist: a comprehensive web server for comparative metagenomics. Nucleic Acids Res 40: W88-95.
30. van den Berg RA, Hoefsloot HC, Westerhuis JA, Smilde AK, van der Werf MJ (2006) Centering, scaling, and transformations: improving the biological information content of metabolomics data. BMC Genomics 7: 142.
31. Xia J, Wishart DS (2002) Metabolomic Data Processing, Analysis, and Interpretation Using MetaboAnalyst. Current Protocols in Bioinformatics: John Wiley & Sons, Inc.
32. Janes KA, Yaffe MB (2006) Data-driven modelling of signal-transduction networks. Nat Rev Mol Cell Biol 7: 820-828. (Pubitemid 44627475)
33. Westerhuis JA, Hoefsloot HCJ, Smit S, Vis DJ, Smilde AK, et al. (2008) Assessment of PLSDA cross validation. Metabolomics 4: 81-89. (Pubitemid 351217591)
34. Vergara D, Simeone P, del Boccio P, Toto C, Pieragostino D, et al. (2013) Comparative proteome profiling of breast tumor cell lines by gel electrophoresis and mass spectrometry reveals an epithelial mesenchymal transition associated protein signature. Mol Biosyst 9: 1127-1138.
35. Wiklund S, Nilsson D, Eriksson L, Sjöström M, Wold S, et al. (2007) A randomization test for PLS component selection. Journal of Chemometrics 21: 427-439.
36. Bjerrum JT, Nielsen OH, Hao F, Tang H, Nicholson JK, et al. (2010) Metabonomics in ulcerative colitis: diagnostics, biomarker identification, and insight into the pathophysiology. J Proteome Res 9: 954-962.
37. Chan EC, Pasikanti KK, Nicholson JK (2011) Global urinary metabolic profiling procedures using gas chromatography-mass spectrometry. Nat Protoc 6: 1483-1499.
38. Sun H (2004) A universal molecular descriptor system for prediction of logP, logS, logBB, and absorption. J Chem Inf Comput Sci 44: 748-757.
39. Eriksson L, Umetrics AB (2006) Multi- and Megavariate Data Analysis, Part 1, Basic Principles and Applications: Umetrics AB.
40. Berglund L, Bjorling E, Oksvold P, Fagerberg L, Asplund A, et al. (2008) A genecentric Human Protein Atlas for expression profiles based on antibodies. Mol Cell Proteomics 7: 2019-2027.
41. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, et al. (2010) Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 28: 1248-1250.
42. Levanen B, Wheelock AM (2009) Troubleshooting image analysis in 2DE. Methods Mol Biol 519: 113-129.
43. Kleno TG, Leonardsen LR, Kjeldal HO, Laursen SM, Jensen ON, et al. (2004) Mechanisms of hydrazine toxicity in rat liver investigated by proteomics and multivariate data analysis. Proteomics 4: 868-880. (Pubitemid 38339164)
44. Norden B, Broberg P, Lindberg C, Plymoth A (2005) Analysis and understanding of high-dimensionality data by means of multivariate data analysis. Chem Biodivers 2: 1487-1494. (Pubitemid 41762900)
45. Marengo E, Robotti E, Bobba M, Milli A, Campostrini N, et al. (2008) Application of partial least squares discriminant analysis and variable selection procedures: a 2D-PAGE proteomic study. Anal Bioanal Chem 390: 1327-1342.
46. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, et al. (2005) Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8: 393-406. (Pubitemid 41579834)
47. Minagawa H, Honda M, Miyazaki K, Tabuse Y, Teramoto R, et al. (2008) Comparative proteomic and transcriptomic profiling of the human hepatocellular carcinoma. Biochem Biophys Res Commun 366: 186-192. (Pubitemid 350297227)
48. Gygi SP, Rochon Y, Franza BR, Aebersold R (1999) Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 19: 1720-1730. (Pubitemid 29098230)
49. Guerra E, Trerotola M, Dell' Arciprete R, Bonasera V, Palombo B, et al. (2008) A bi-cistronic CYCLIN D1-TROP2 mRNA chimera demonstrates a novel oncogenic mechanism in human cancer. Cancer Res 68: 8113-8121.
50. Trerotola M, Cantanelli P, Guerra E, Tripaldi R, Aloisi AL, et al. (2013) Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene 32 222-233.
51. Guerra E, Trerotola M, Aloisi AL, Tripaldi R, Vacca G, et al. (2013) The Trop-2 signalling network in cancer growth. Oncogene 32: 1594-1600.
52. Rigamonti D, Bauer JH, De-Fraja C, Conti L, Sipione S, et al. (2000) Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci 20: 3705-3713. (Pubitemid 30266233)
53. Pitts A, Dailey K, Newington JT, Chien A, Arseneault R, et al. (2012) Dithiolbased compounds maintain expression of antioxidant protein peroxiredoxin 1 that counteracts toxicity of mutant huntingtin. J Biol Chem 287: 22717-22729.
54. Erdmann S, Senkel S, Arndt T, Lucas B, Lausen J, et al. (2007) Tissue-specific transcription factor HNF4alpha inhibits cell proliferation and induces apoptosis in the pancreatic INS-1 beta-cell line. Biol Chem 388: 91-106. (Pubitemid 46090178)
55. Lucas B, Grigo K, Erdmann S, Lausen J, Klein-Hitpass L, et al. (2005) HNF4alpha reduces proliferation of kidney cells and affects genes deregulated in renal cell carcinoma. Oncogene 24: 6418-6431. (Pubitemid 41486475)
56. Spath GF, Weiss MC (1998) Hepatocyte nuclear factor 4 provokes expression of epithelial marker genes, acting as a morphogen in dedifferentiated hepatoma cells. J Cell Biol 140: 935-946. (Pubitemid 28141230)
57. Hwang-Verslues WW, Sladek FM (2008) Nuclear receptor hepatocyte nuclear factor 4alpha1 competes with oncoprotein c-Myc for control of the p21/WAF1 promoter. Mol Endocrinol 22: 78-90.
58. Walesky C, Edwards G, Borude P, Gunewardena S, O'Neil M, et al. (2013) Hepatocyte nuclear factor 4 alpha deletion promotes diethylnitrosamine-induced hepatocellular carcinoma in rodents. Hepatology 57: 2480-2490.
59. Kohn KW (1999) Molecular interaction map of the mammalian cell cycle control and DNA repair systems. Mol Biol Cell 10: 2703-2734.
60. Orian A, van Steensel B, Delrow J, Bussemaker HJ, Li L, et al. (2003) Genomic binding by the Drosophila Myc, Max, Mad/Mnt transcription factor network. Genes Dev 17: 1101-1114. (Pubitemid 36534985)
61. Meyer N, Penn LZ (2008) Reflecting on 25 years with MYC. Nat Rev Cancer 8: 976-990.
62. Sebastian C, Zwaans BM, Silberman DM, Gymrek M, Goren A, et al. (2013) The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell 151: 1185-1199.
63. Morrish F, Isern N, Sadilek M, Jeffrey M, Hockenbery DM (2009) c-Myc activates multiple metabolic networks to generate substrates for cell-cycle entry. Oncogene 28: 2485-2491.
64. Masui K, Tanaka K, Akhavan D, Babic I, Gini B, et al. (2013) mTOR Complex 2 Controls Glycolytic Metabolism in Glioblastoma through FoxO Acetylation and Upregulation of c-Myc. Cell Metab 18: 726-739.
65. Marie SK, Shinjo SM (2011) Metabolism and brain cancer. Clinics (Sao Paulo) 66 Suppl 1: 33-43.
66. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, et al. (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21: 2683-2710. (Pubitemid 350070717)
67. Ziegler DS, Kung AL, Kieran MW (2008) Anti-apoptosis mechanisms in malignant gliomas. J Clin Oncol 26: 493-500. (Pubitemid 351171704)
68. Seyfried TN, Sanderson TM, El-Abbadi MM, McGowan R, Mukherjee P (2003) Role of glucose and ketone bodies in the metabolic control of experimental brain cancer. Br J Cancer 89: 1375-1382. (Pubitemid 37363431)
69. Galarraga J, Loreck DJ, Graham JF, DeLaPaz RL, Smith BH, et al. (1986) Glucose metabolism in human gliomas: correspondence of in situ and in vitro metabolic rates and altered energy metabolism. Metab Brain Dis 1: 279-291.
70. Liang S, Shen G, Liu Q, Xu Y, Zhou L, et al. (2009) Isoform-specific expression and characterization of 14-3-3 proteins in human glioma tissues discovered by stable isotope labeling with amino acids in cell culture-based proteomic analysis. Proteomics Clin Appl 3: 743-753.
71. Yang X, Cao W, Zhou J, Zhang W, Zhang X, et al. (2011) 14-3-3zeta positive expression is associated with a poor prognosis in patients with glioblastoma. Neurosurgery 68: 932-938; discussion 938.
72. Arora S, Matta A, Shukla NK, Deo SV, Ralhan R (2005) Identification of differentially expressed genes in oral squamous cell carcinoma. Mol Carcinog 42: 97-108.
73. Jang JS, Cho HY, Lee YJ, Ha WS, Kim HW (2004) The differential proteome profile of stomach cancer: identification of the biomarker candidates. Oncol Res 14: 491-499. (Pubitemid 39551562)
74. Somiari RI, Somiari S, Russell S, Shriver CD (2005) Proteomics of breast carcinoma. J Chromatogr B Analyt Technol Biomed Life Sci 815: 215-225. (Pubitemid 40126403)
75. Huber E, Vlasny D, Jeckel S, Stubenrauch F, Iftner T (2004) Gene profiling of cottontail rabbit papillomavirus-induced carcinomas identifies upregulated genes directly Involved in stroma invasion as shown by small interfering RNA-mediated gene silencing. J Virol 78: 7478-7489. (Pubitemid 38915893)
76. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812.
77. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, et al. (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773.
78. Krell D, Assoku M, Galloway M, Mulholland P, Tomlinson I, et al. (2011) Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma. PLoS One 6: e19868.
79. Rahman-Roblick R, Hellman U, Becker S, Bader FG, Auer G, et al. (2008) Proteomic identification of p53-dependent protein phosphorylation. Oncogene 27: 4854-4859.
80. Feng Z, Jin S, Zupnick A, Hoh J, de Stanchina E, et al. (2006) p53 tumor suppressor protein regulates the levels of huntingtin gene expression. Oncogene 25: 1-7. (Pubitemid 43049998)
81. Agrawal P, Yu K, Salomon AR, Sedivy JM (2010) Proteomic profiling of Myc-associated proteins. Cell Cycle 9: 4908-4921.
82. Maeda Y, Seidel SD, Wei G, Liu X, Sladek FM (2002) Repression of hepatocyte nuclear factor 4alpha tumor suppressor p53: involvement of the ligand-binding domain and histone deacetylase activity. Mol Endocrinol 16: 402-410. (Pubitemid 34131234)
83. Waterman MJ, Stavridi ES, Waterman JL, Halazonetis TD (1998) ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nat Genet 19: 175-178. (Pubitemid 28248801)
84. Bradley SV, Holland EC, Liu GY, Thomas D, Hyun TS, et al. (2007) Huntingtin interacting protein 1 is a novel brain tumor marker that associates with epidermal growth factor receptor. Cancer Res 67: 3609-3615. (Pubitemid 46762145)
85. Chou YT, Lin HH, Lien YC, Wang YH, Hong CF, et al. (2010) EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. Cancer Res 70: 8822-8831.
86. Oksvold MP, Huitfeldt HS, Langdon WY (2004) Identification of 14-3-3zeta as an EGF receptor interacting protein. FEBS Lett 569: 207-210. (Pubitemid 38844619)
87. Martinho O, Granja S, Jaraquemada T, Caeiro C, Miranda-Goncalves V, et al. (2012) Downregulation of RKIP is associated with poor outcome and malignant progression in gliomas. PLoS One 7: e30769.